Hims & Hers Health (NYSE: HIMS), once a niche telehealth provider focused on men’s wellness, has rapidly transformed into a formidable player in the broader digital health ecosystem. HIMS stock has ...

That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...

Hims & Hers Health first-quarter revenue more than doubled as subscribers rose 38%, while its second-quarter sales outlook ...

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

Hims is doubling down on ambitionand it just brought in a heavy hitter to do it. Nader Kabbani, the architect behind Amazon ...

Ezra's primary competitor is Prenuvo, another full-body MRI scanning startup. In February, Prenuvo announced that it closed a ...

Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to ...

Hims & Hers Health on Monday announced Nader Kabbani, a former Amazon executive who helped establish many of its health-care ...

Hims & Hers Health appoints former Amazon executive Nader Kabbani as its chief operating officer. The telehealth-consultation platform on Monday said Kabbani will oversee operations as the company ...

Merck's $3.9B SpringWorks deal, Hims & Hers' Wegovy partnership, CVS exiting Obamacare, and FDA updates on key drugs.

Hims & Hers Health (NYSE:HIMS) stock spikes, risking a short squeeze given its elevated short interest. Read more here.